Literature DB >> 23604614

Type І hyper IgM syndrome with novel mutation from India.

Rashid H Merchant1, Javed Ahmed, Noor Ahmed, Capucine Picard.   

Abstract

Hyper IgM syndrome is a primary immunodeficiency disorder characterized by normal or raised levels of immunoglobulin (Ig) M with low or absent IgG, IgA, and IgE. Five genetic causes of Hyper IgM have been identified. CD40L is deficient on T cells in Type І Hyper IgM, leading to defective interaction between T and B lymphocytes and consequently an inability to switch from production of IgM to other classes of antibodies. This manuscript reports a patient with X linked Hyper IgM (XHIGM) syndrome caused by a novel mutation in the CD40 Ligand (CD40L) gene and a favorable outcome after bone marrow transplantation.

Entities:  

Mesh:

Year:  2013        PMID: 23604614     DOI: 10.1007/s12098-013-1029-4

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  8 in total

1.  Correction of the hyper-IgM syndrome after liver and bone marrow transplantation.

Authors:  N Hadzić; A Pagliuca; M Rela; B Portmann; A Jones; P Veys; N D Heaton; G J Mufti; G Mieli-Vergani
Journal:  N Engl J Med       Date:  2000-02-03       Impact factor: 91.245

2.  Clinical spectrum of X-linked hyper-IgM syndrome.

Authors:  J Levy; T Espanol-Boren; C Thomas; A Fischer; P Tovo; P Bordigoni; I Resnick; A Fasth; M Baer; L Gomez; E A Sanders; M D Tabone; D Plantaz; A Etzioni; V Monafo; M Abinun; L Hammarstrom; T Abrahamsen; A Jones; A Finn; T Klemola; E DeVries; O Sanal; M C Peitsch; L D Notarangelo
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

3.  Bone marrow transplantation for CD40 ligand deficiency: a single centre experience.

Authors:  K Khawaja; A R Gennery; T J Flood; M Abinun; A J Cant
Journal:  Arch Dis Child       Date:  2001-06       Impact factor: 3.791

4.  X-linked hyper-IgM syndrome with CD40LG mutation: two case reports and literature review in Taiwanese patients.

Authors:  Hu-Yuan Tsai; Hsin-Hui Yu; Yin-Hsiu Chien; Kuan-Hua Chu; Yu-Lung Lau; Jyh-Hong Lee; Li-Chieh Wang; Bor-Luen Chiang; Yao-Hsu Yang
Journal:  J Microbiol Immunol Infect       Date:  2012-09-24       Impact factor: 4.399

5.  Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome.

Authors:  K Seyama; S Nonoyama; I Gangsaas; D Hollenbaugh; H F Pabst; A Aruffo; H D Ochs
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

Review 6.  The role of CD40 in the regulation of humoral and cell-mediated immunity.

Authors:  F H Durie; T M Foy; S R Masters; J D Laman; R J Noelle
Journal:  Immunol Today       Date:  1994-09

Review 7.  X-linked immunodeficiency with hyper-IgM (XHIM).

Authors:  L D Notarangelo; A R Hayward
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

8.  Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2).

Authors:  P Revy; T Muto; Y Levy; F Geissmann; A Plebani; O Sanal; N Catalan; M Forveille; R Dufourcq-Labelouse; A Gennery; I Tezcan; F Ersoy; H Kayserili; A G Ugazio; N Brousse; M Muramatsu; L D Notarangelo; K Kinoshita; T Honjo; A Fischer; A Durandy
Journal:  Cell       Date:  2000-09-01       Impact factor: 41.582

  8 in total
  3 in total

1.  X-linked hyper-IgM syndrome with eosinophilia in a male child: A case report.

Authors:  L I Guo; B O Chen; Bin Xu; Meiping Lu; Botao Ning; Zhenjie Chen
Journal:  Exp Ther Med       Date:  2015-02-05       Impact factor: 2.447

Review 2.  Primary immunodeficiencies associated with eosinophilia.

Authors:  Behdad Navabi; Julia Elizabeth Mainwaring Upton
Journal:  Allergy Asthma Clin Immunol       Date:  2016-05-24       Impact factor: 3.406

Review 3.  X-linked hyper IgM syndrome with severe eosinophilia: a case report and review of the literature.

Authors:  He Li; Yang Cao; Jijun Ma; Chongwei Li
Journal:  BMC Pediatr       Date:  2022-04-04       Impact factor: 2.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.